期刊文献+

宫颈癌组织中ANXA8、PGRMC1和miR-92a表达水平及其与临床病理特征的关系

Expression of ANXA8,PGRMC1,and miR-92a in Cervical Cancer and Their Relationship with Clinicopathological Features
下载PDF
导出
摘要 目的 探究宫颈癌患者癌组织中膜联蛋白A8(annexin A8, ANXA8)、孕激素受体膜组分1(progesterone receptor membrane component 1,PGRMC1)以及微小核糖核酸-92a(micro RNA-92a,mi R-92a)的表达及其与临床病理特征的关系。方法 收集2020年1月至2022年3月宜宾市第二人民医院接治的69例宫颈癌患者的宫颈癌和癌旁正常组织69例,采用免疫组织化学法检测ANXA8和PGRMC1阳性率,Western blot检测ANXA8和PGRMC1蛋白表达,RT-PCR法检测ANXA8和PGRMC1 m RNA以及mi R-92a表达水平。此外,分析ANXA8、PGRMC1与mi R-92a表达的线性相关性及其与宫颈癌患者临床病理特征的关系。结果 宫颈癌组织中ANXA8和PGRMC1阳性率(76.81%、72.46%)高于癌旁正常组织(4.35%、7.25%),mi R-92a表达量高于癌旁正常组织(P <0.05)。FIGO分期越高、分化程度越低以及具有淋巴结转移和宫旁浸润,ANXA8和PGRMC1阳性率以及mi R-92a表达量越高(P <0.05)。结论 ANXA8、PGRMC1和mi R-92a在宫颈癌组织中高表达,与宫颈癌肿瘤分期、分化程度、转移和浸润等病理特征有关,可为宫颈癌患者的病理学评估提供可靠依据。 Objective To investigate the expression of ANXA8,PGRMC1,and miR-92a in cervical cancer tissues and their relationship with clinicopathological features.Methods A total of 69 cervical cancer patients treated at the Second People’sHospital of Yibin City from January 2020 to March 2022 were included in this study.Cervical cancer tissues and adjacent normal tissues from these patients were collected for analysis.Immunohistochemistry was used to detect the positivity of ANXA8 and PGRMC1.Western blot was performed to analyze the protein expression of ANXA8 and PGRMC1.RT-PCR was used to measure the mRNA levels of ANXA8 and PGRMC1,as well as the expression level of miR-92a.The linear correlation among ANXA8,PGRMC1,and miR-92a expression levels,as well as their relationships with the clinical pathological features of cervical cancer patients,were analyzed.Results The positive rates of ANXA8 and PGRMC1 in cervical cancer tissues(76.81%,72.46%)were significantly higher than adjacent tissues(4.35%and 7.25%),and the expression level of miR-92a was significantly higher than adjacent tissues(P<0.05).With higher FIGO stage,lower differentiation degree,lymph node metastasis,and parametrial infiltration,the positivity rates of ANXA8 and PGRMC1 as well as the expression level of miR-92a were higher(P<0.05).Conclusion ANXA8,PGRMC1,and miR-92a are highly expressed in cervical cancer tissues,and are related to the pathological characteristics such as tumor staging,differentiation degree,metastasis,and invasion.They can provide a reliable basis for the pathological evaluation of cervical cancer patients.
作者 闵志波 周冉 蒲丹 杨涛 MIN Zhibo;ZHOU Ran;PU Dan;YANG Tao(Dept.of Pathology,The 2nd People’s Hospital of Yibin,Yibin Sichuan 644000,China)
出处 《昆明医科大学学报》 CAS 2024年第8期101-108,共8页 Journal of Kunming Medical University
基金 宜宾市卫生健康医学基金资助项目(2022YW007)。
关键词 宫颈癌 膜联蛋白A8 孕激素受体膜组分1 微小核糖核酸-92a 临床病理特征 Cervical cancer Annexin A8 Progesterone receptor membrane component 1 microRNA-92a Clinicopathological features
  • 相关文献

参考文献10

二级参考文献67

  • 1Jemal A,Siegel R,Ward E. Cancer Statistics,2007[J].{H}CA-A Cancer Journal for Clinicians,2007.43-66.
  • 2Howe HL,Wu X,Ries LA. Annual report to the nation on the status of cancer,1975-2003,featuring cancer among U.S.Hispanic/Latino populations[J].{H}CANCER,2006,(08):1711-1742.
  • 3Sherman ME,Wang SS,Carreon J. Mortality trends for cervical squamous and adenocarcinoma in the United States.Relation to incidence and survival[J].{H}CANCER,2005,(06):1258-1264.
  • 4Parkin DM,Bray F,Ferlay J. Global cancer statistics,2002[J].{H}CA-A Cancer Journal for Clinicians,2005.74-108.
  • 5Kamangar F,Dores GM,Anderson WF. Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world[J].{H}Journal of Clinical Oncology,2006,(14):2137-2150.
  • 6Villa LL,Costa RL,Petta CA. Prophylactic quadrivalent human papillomavirus(types 6,11,16,and 18)L1 virus-like particle vaccine in young women:a randomized double-blind placebo-controlled multicentre phase II efifcacy trial[J].{H}LANCET ONCOLOGY,2005.271-278.
  • 7Ault KA,Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2,grade 3,and adenocarcinoma in situ:a combined analysis of four randomised clinical trials[J].{H}LANCET,2007,(9576):1861-1868.
  • 8FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions[J].{H}New England Journal of Medicine,2007,(19):1915-1927.
  • 9Arbyn M,Dillner J. Review of current knowledge on HPV vaccination:an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening[J].{H}Journal of Clinical Virology,2007,(03):189-197.
  • 10American College of Obstetricians and Gynecologists. ACOG practice bulletin.Diagnosis and treatment of cervical carcinomas.Number 35,May 2002[J].{H}International Journal of Gynecology & Obstetrics,2002.79-91.

共引文献269

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部